These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25758352)

  • 21. Experience Learned and Perspectives on Using Model-Integrated Evidence in the Regulatory Context for Generic Drug Products-a Meeting Report.
    Tsakalozou E; Fang L; Bi Y; van den Heuvel M; Ahmed T; Tsang YC; Lionberger R; Rostami-Hodjegan A; Zhao L
    AAPS J; 2024 Jan; 26(1):14. PubMed ID: 38200397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Model-Based Approach for Designing an Efficient Bioequivalence Study for Highly Variable Drugs.
    Song E; Lee W; Kim BH
    Pharmaceuticals (Basel); 2021 Oct; 14(11):. PubMed ID: 34832883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I Studies: Innovations and Issues.
    Beninger P
    Clin Ther; 2024 Feb; 46(2):85-89. PubMed ID: 38342708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biocompatibility Considerations for Orally Inhaled and Nasal Drug Products and Other Drug--Device Combination Products.
    Stults CLM; Lanning CL; Nagao LM; Conners J
    PDA J Pharm Sci Technol; 2024 Feb; 78(1):125-139. PubMed ID: 37973193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulatory Considerations for Approval of Generic Inhalation Drug Products in the US, EU, Brazil, China, and India.
    Lee SL; Saluja B; García-Arieta A; Santos GM; Li Y; Lu S; Hou S; Rebello J; Vaidya A; Gogtay J; Purandare S; Lyapustina S
    AAPS J; 2015 Sep; 17(5):1285-304. PubMed ID: 26002510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current Scientific and Regulatory Approaches for Development of Orally Inhaled and Nasal Drug Products: Overview of the IPAC-RS/University of Florida Orlando Inhalation Conference.
    Hochhaus G; Davis-Cutting C; Oliver M; Lee SL; Lyapustina S
    AAPS J; 2015 Sep; 17(5):1305-11. PubMed ID: 26033698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In Vitro Testing for Orally Inhaled Products: Developments in Science-Based Regulatory Approaches.
    Forbes B; Bäckman P; Christopher D; Dolovich M; Li BV; Morgan B
    AAPS J; 2015 Jul; 17(4):837-52. PubMed ID: 25940082
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of Orally Inhaled Drug Products.
    Hochhaus G; Horhota S; Hendeles L; Suarez S; Rebello J
    AAPS J; 2015 May; 17(3):769-75. PubMed ID: 25762449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Bioequivalence Approach for Generic Narrow Therapeutic Index Drugs: Evaluation of the Reference-Scaled Approach and Variability Comparison Criterion.
    Jiang W; Makhlouf F; Schuirmann DJ; Zhang X; Zheng N; Conner D; Yu LX; Lionberger R
    AAPS J; 2015 Jul; 17(4):891-901. PubMed ID: 25840883
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two-stage designs for cross-over bioequivalence trials.
    Kieser M; Rauch G
    Stat Med; 2015 Jul; 34(16):2403-16. PubMed ID: 25809815
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Implications in medical imaging of the new ICRP thresholds for tissue reactions.
    Vañó E; Miller DL; Dauer L
    Ann ICRP; 2015 Jun; 44(1 Suppl):118-28. PubMed ID: 25816265
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genomics in the land of regulatory science.
    Tong W; Ostroff S; Blais B; Silva P; Dubuc M; Healy M; Slikker W
    Regul Toxicol Pharmacol; 2015 Jun; 72(1):102-6. PubMed ID: 25796433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Secondary pharmacology data to assess potential off-target activity of new drugs: a regulatory perspective.
    Papoian T; Chiu HJ; Elayan I; Jagadeesh G; Khan I; Laniyonu AA; Li CX; Saulnier M; Simpson N; Yang B
    Nat Rev Drug Discov; 2015 Apr; 14(4):294. PubMed ID: 25792260
    [No Abstract]   [Full Text] [Related]  

  • 34. Applications of In Vitro-In Vivo Correlations in Generic Drug Development: Case Studies.
    Kaur P; Jiang X; Duan J; Stier E
    AAPS J; 2015 Jul; 17(4):1035-9. PubMed ID: 25896303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding the Essentialities in Establishing the Bioequivalence of Oral Inhalation Drug Products to be Marketed in the USA.
    Fernandes SD; Koland M
    Ther Innov Regul Sci; 2020 Jul; 54(4):738-748. PubMed ID: 32557296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sensitivity Analysis and Uncertainty Quantification of Nanoparticle Deposition from Tongue Morphological Variations.
    Yang T; Si X; Xi J
    Life (Basel); 2024 Mar; 14(3):. PubMed ID: 38541730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of Physicochemical Properties of Budesonide Micro-Suspensions on Their Expected Lung Delivery Using a Vibrating Mesh Nebulizer.
    Dobrowolska K; Emeryk A; Janeczek K; Krzosa R; Pirożyński M; Sosnowski TR
    Pharmaceutics; 2023 Feb; 15(3):. PubMed ID: 36986613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bioequivalence study of ipratropium bromide inhalation aerosol using PBPK modelling.
    Zhang J; Wu K; Liu B; Hou S; Li X; Ye X; Liu J; He Q
    Front Med (Lausanne); 2023; 10():1056318. PubMed ID: 36824609
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advancements in the Design and Development of Dry Powder Inhalers and Potential Implications for Generic Development.
    Mohan AR; Wang Q; Dhapare S; Bielski E; Kaviratna A; Han L; Boc S; Newman B
    Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36432683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dry Powder Inhalers in the Digitalization Era: Current Status and Future Perspectives.
    Xiroudaki S; Schoubben A; Giovagnoli S; Rekkas DM
    Pharmaceutics; 2021 Sep; 13(9):. PubMed ID: 34575530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.